Zicronapine ( , previously known as Lu 31-130) is an
atypical antipsychotic
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs (antipsychotic drugs in general are also known as major tranquilizers and ne ...
medication
formerly under development by
H. Lundbeck A/S. In
phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to
olanzapine
Olanzapine (sold under the trade name Zyprexa among others) is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is t ...
.
Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. ''In vitro'' and ''in vivo'' it has shown potent antagonistic effects at dopamine
D1,
D2 and serotonin
5HT2A receptors.
In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic
Lu AF35700 (a
prodrug of
Lu AF356152).
References
External links
*
Abandoned drugs
Atypical antipsychotics
1-Aminoindanes
Chloroarenes
Piperazines
{{Psychiatry-stub